Effect of switch from EquMet combination tablet to METOANA combination tablet

Effect of switch from metformin / vildagliptin fixed-dose combination tablet to metformin / anagliptin fixed-dose combination tablet - Effect of switch from metformin / vildagliptin fixed-dose combination tablet to metformin / anagliptin fixed-dose combination tablet

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000040960

Enrollment

150

Registered

2020-06-30

Start date

2020-02-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes mellitus

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patients with type 2 diabetes mellitus 2. Male and female aged of 20 years or older 3. Patients who switched from metformin / vildagliptin fixed-dose combination tablet (twice daily) to metformin / anagliptin fixed-dose combination tablet (twice daily) in Kurihara Clinic of Internal Medicine between November 21st, 2018 and March 31st, 2019, and continued visiting the clinic for 6 months or longer (switch group) 4. Patients who continued metformin / vildagliptin fixed-dose combination tablet (twice daily) after the first test between November 21st, 2018 and March 31st, 2019, and continued visiting Kurihara Clinic of Internal Medicine for 6 months or longer (non-switch group) 5. Patients who continued metformin / vildagliptin fixed-dose combination tablet (twice daily) for 3 months or longer before the switch to metformin / anagliptin fixed-dose combination tablet in switch group or before the first test in non-switch group

Exclusion criteria

Exclusion criteria: 1. Patients who are treated by combination of metformin / vildagliptin fixed-dose combination tablet LD and HD 2. Patients who changed the dose of metformin / vildagliptin fixed-dose combination tablet during the metformin / vildagliptin fixed-dose combination tablet administration period 3. Patients who changed the dose of metformin / anagliptin fixed-dose combination tablet during the metformin / anagliptin fixed-dose combination tablet administration period 4. Patients who changed the type or dose of hypoglycemic agents or antihyperlipidemic agents 5. Patients who are treated by dialysis or patients with severe renal impairment (eGFR < 30 mL/min/1.73m2) at baseline 6. Female patients who are pregnant, breastfeeding, possibly pregnant, or planning to become pregnant 7. Patients who denied the use of clinical medical records to the study 8. Patients with any conditions that physicians thought to be inappropriate to participate in the study such as poor adherence

Design outcomes

Primary

Measure	Time frame
Time-dependent change in HbA1c in switch group and non-switch group	—

Countries

Japan

Contacts

Public ContactYoshio Kurihara

Kurihara Clinic of Internal Medicine Internal Medicine

ykuri@yg7.so-net.ne.jp0118923522

Outcome results